The future of early cancer detection is now

A ground breaking early detection platform focused on women’s health

The future of early cancer detection is now​

A ground breaking early detection platform focused on women’s health

GlycoLocate™

Our revolutionary tumor marker ganglioside platform is paving the way for life-saving early cancer detection

AKRIVIS GD™

A novel blood test harnessing the power of tumor marker gangliosides to detect early-stage ovarian cancer

Welcome to the future

GlycoLocate™: An AI Enabled Early Detection Cancer Platform

AOA Dx is pioneering the field of glycolipids through the utilization of tumor marker gangliosides, the next class of biomarkers in early cancer detection. AOA Dx is developing the first and only technology utilizing these markers with data science, providing remarkable insights into early cancer detection.

Who We Are

Devoted to innovation in women’s health, AOA Dx is a team of industry experts and entrepreneurs committed to bringing impactful and cost-effective medical technologies from research and development into the hands of providers and patients.

Do you want to be a part of transforming women's health through early cancer detection?

Join us on our mission

We’re looking for teammates dedicated to raising the bar in women’s health.

Featured In

Get in Touch